Sanofi's subcutaneous formulation of isatuximab has been approved by the FDA
发布时间:
2026-07-21 00:00
On July 9, 2026, the US Food and Drug Administration (FDA) approved the subcutaneous injection formulation of Sanofi’s isatuximab-irfc (brand name Sarclisa Escena) for use in combination with standard regimens in the treatment of adult patients with relapsed/refractory multiple myeloma (MM), covering all existing indications for intravenous (IV) formulations.
Previously, in April 2026, the FDA announced an extension of the target review date for the Prescription Drug Fee Act (PDUFA) from April 22 to July 23, but the approval was ultimately granted ahead of schedule on July 9. In the EU, the CHMP of the EMA provided a positive opinion in March 2026, and Japan has also approved the subcutaneous formulation.
This approval makes isatuximab the first anti-tumor drug that can be administered through an On-Body Inf(OBI), and it is also the only multiple myeloma treatment drug in the United States that supports both on-body infusion and manual subcutaneous injection as modes of drug delivery. The core selling point of isatuximab’s subcutaneous formulation this time is not just changing the needle, but rather changing the entire logic: (1) Extreme compression of time cost: Traditional intravenous injection often takes several hours, but with the CirCLIQ® OBI device, the drug is automatically infused subcutaneously through a short 30G needle, significantly reducing the administration time, and patients no longer have to be tied to the infusion rack. (2) Strong support from safety data: The results of the key Phase III IRAKLIA study show that the objective response rate (ORR) in the subcutaneous injection group was 71.1%, compared to 70.5% in the intravenous injection group, confirming non-inferior efficacy. What’s even more impressive is the safety, with systemic infusion reactions plummeting from 25% in intravenous injection to 1.5%, and injection site reactions mostly being grade I mild reactions, with an incidence rate of only 0.4%. (3) Autonomy brought by OBI: This is the first myeloma drug in the United States to support the dual mode of “wearable automatic injection + manual subcutaneous injection”. Patients can walk around with a small device on their back, and this “de-hospitalization” drug delivery experience is precisely the physical foundation for the implementation of chronic disease management for tumors.
Nowadays, the survival period for patients with multiple myeloma has been significantly improved. Fighting cancer is no longer a short-term battle, but a protracted war that can last for years. Subcutaneous preparations targeting PD-1, HER2, and other targets have been launched successively, confirming the industry trend: the future main battlefield for anti-tumor treatment is outpatient clinics and homes, rather than hospital wards. Relying on subcutaneous administration combined with intelligent devices, long-term survival patients can break free from the constraints of hospital settings, allowing treatment to be integrated into their daily lives.
Sarclisa (Isatuximab) is a monoclonal antibody that exerts unique anti-tumor activity by binding to specific epitopes of the CD38 receptor on multiple myeloma cells. It functions through multiple mechanisms, including inducing programmed cell death of tumor cells and exerting immunomodulatory activity.
CD38 is widely and uniformly expressed on multiple myeloma (MM) cells, and monoclonal antibodies targeting CD38 have become an important new anti-MM drug, serving as an ideal target for drug development in multiple myeloma. Isatuximab is a chimeric IgG1-κ type antibody, whose unique binding epitope and structure confer stronger antibody affinity and enhanced anti-tumor activity. It possesses the ability to directly induce apoptosis, maintaining therapeutic efficacy even in the absence of effector cell cross-linking. Isatuximab potently and specifically inhibits CD38 enzyme activity, overcoming the immunosuppression caused by CD38 catalytic product adenosine (ADO) to achieve better therapeutic effects.
In addition, isatuximab has a less dependent anti-MM effect on complement-dependent cytotoxicity (CDC), thus avoiding the complement inhibition effect caused by high expression of CD55 in 1q-amplified MM patients. It is expected to overcome 1q resistance through a potent killing mechanism. Therefore, with its novel mechanism and unique advantages, isatuximab demonstrates broad application prospects in the treatment of myeloma.
Currently, for isatuximab Injection, there are three patents listed on the patent information registration platform for drugs marketed in China by Sanofi. As shown in the list below, its basic patent (200780038983.6) is set to expire next year. Upon expiration, there may be companies applying for generic versions of the drug.
|
Serial Number |
Patent application number |
The type and number of patent protection involved |
Expiration date |
status |
|
1 |
200780038983.6 |
Sequence structure (1-3, 7-13) + Usage (24, 30, 31) |
2027-10-16 |
in force |
|
2 |
201380063714.0 |
Usage (1-4, 6-16) |
2033-12-06 |
in force |
|
3 |
201610701653.1 |
Usage (1-6) |
2031-12-08 |
in force |
References:
1. https://mp.weixin.qq.com/s/mos2iqDcmAX6UIfNKNRNBA
2. https://finance.sina.com.cn/wm/2026-07-13/doc-inihsisv4221944.shtml
立即咨询
如果您对我们的产品感兴趣,请留下您的电子邮件,我们将尽快与您联系,谢谢!